Neurocognitive enhancement: Ethical considerations for an emerging subspecialty

Applied Neuropsychology

Volumn 13, Issue 2, 2006, Pages 125-136

  Bush, Shane S ^a  

^a NONE   (United States)

Author keywords

Biotechnology; Ethics; Neurocognitive enhancement; Neuroethics; Neuropsychology

Indexed keywords

ADRENALIN; ANTIINFLAMMATORY AGENT; ATOMOXETINE; CHOLINESTERASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DONEPEZIL; GINKGO BILOBA EXTRACT; HYPOCHOLESTEROLEMIC AGENT; MEMANTINE; MODAFINIL; NONSTEROID ANTIINFLAMMATORY AGENT;

BENEFICENCE; BIOTECHNOLOGY; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR DISEASE; COGNITION; CONSUMER; EXERCISE; HUMAN; HUMAN DIGNITY; HUMAN RIGHTS; JUSTICE; MEDICAL ETHICS; NEUROIMAGING; NEUROPSYCHOLOGY; NEUROSURGERY; POLICY; PRACTICE GUIDELINE; PSYCHOLOGIST; PSYCHOPHARMACOLOGY; RESPONSIBILITY; REVIEW;

EID: 33750341561     PISSN: 09084282     EISSN: 15324826     Source Type: Journal    
DOI: 10.1207/s15324826an1302_7     Document Type: Review

References (70)

1. Agency for Healthcare Research and Quality. (2003, September). Hyperbaric oxygen therapy for brain injury, cerebral palsy, and stroke. Summary, Evidence Report/Technology Assessment: Number 85. AHRQ Publication Number 03-E049. Retrieved December 15, 2004, from http://www.ahrq.gov/clinic/epcsums/hypoxsum. htm
2. Aisen, P. S., Davis, K. L., Berg, J. D., Schafer, K., Campbell, K., Thomas, R. G., et al. (2000). A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology, 54, 588-593.
3. American Psychological Association. (2002). Ethical principles of psychologists and code of conduct. American Psychologist, 57, 1060-1073.
4. Anand, S., & Hotson, J. (2002). Transcranial magnetic stimulation: Neurophysiological applications and safety. Brain and Cognition, 50, 366-386.
5. Babcock, Q., & Byrne, T. (2000). Student perceptions of methylphenidate abuse at a public liberal arts college. Journal of the American College of Health, 49, 143-145.
6. Ball, K., Berch, D. B., Helmers, K. F., Jobe, J. B., Leveck, M. D., Marsiske, M., et al. (2002). Effects of cognitive training interventions with older adults. Journal of the American Medical Association, 288, 2271-2281.
7. Banja, J. (2003). Neuroethics: A report of the 2003 faculty ethics seminar. Retrieved September 1, 2003, from http://ethics.emory.edu/news/ archives/000246.html
8. Bookheimer, S. Y., Strojwas, M. H., Cohen, M. S., Saunders, A. M., Pericak-Vance, M. A., Mazziotta, J. C., et al. (2000). Patterns of brain activation in people at risk for Alzheimer's disease. New England Journal of Medicine, 343, 450-456.
9. Boroojerdi, B., Phipps, M., Kopylev, L., Wharton, C. M., Cohen, L. G., & Grafman, J. (2001). Enhancing analogic reasoning with rTMS over the left prefrontal cortex. Neurology, 56, 526-528.
10. Brioso, C. (2004). Fans wary of steroid-records connection. Retrieved December 27, 2004, from http://www.usatoday.com /sports/2004-12-21-fans-poll- records_x.htm?POE=SPOISVA
11. Burkhard, P. R., Vingerhoets, F. J. G., Berney, A., Bogousslavsky, J., Villemure, J.-G., & Ghika, J. (2004). Suicide after successful deep brain stimulation for movement disorders. Neurology, 63, 2170-2172.
12. Bush, S., & Martin, T. (2004, July 18). Balancing bioethical principles in computer-based memory treatment. Poster presentation, ninth International Conference on Alzheimer's Disease and Related Disorders, Philadelphia.
13. Butefisch, C. M., Khurana, V., Kopylev, L., & Cohen, L. G. (2004). Enhancing encoding of a motor memory in the primary motor cortex by cortical stimulation. Journal of Neurophysiology, 91, 2110-2116.
14. Caballero, J., & Nahata, M. (2004). Do statins slow down Alzheimer's disease? A review. Journal of Clinical Pharmacy and Therapeutics, 29, 209-213.
15. Cahill, L. (2003). Similar neural mechanisms for emotion-induced memory impairment and enhancement. Proceedings of the National Academy of Sciences, 100, 13123-13124.
16. Caldwell, J. J., Caldwell, J., Smythe, N. R., & Hall, K. (2000). A double-blind, placebo-controlled investigation of the efficacy of modafmil for sustaining the alertness and performance of aviators: A helicopter simulator study. Psychopharmacology, 150, 272-282.
17. Canadian Psychological Association. (1991). Canadian code of ethics for psychologists (Rev. ed.). Ottawa, Ontario: Author.
18. Chatterjee, A. (2004). Cosmetic neurology: The controversy over enhancing movement, mentation, and mood. Neurology, 63, 968-974.
19. Dees, R. H. (2004). Slippery slopes, wonder drugs, and cosmetic neurology: The neuroethics of enhancement. Neurology, 63, 951-952.
20. Delagarza, V. W. (2003). Pharmacologic treatment of Alzheimer's disease: An update. American Family Physician, 68, 1365-1372.
21. Diller, L. (1996). The run on Ritalin: Attention deficit disorder and stimulant treatment in the 1990s. Hastings Center Report, 26, 12-14.
22. Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., et al. (2001). Practice parameter: Management of dementia (an evidence-based review). Neurology, 56, 1154-1166.
23. Drazen, J. M. (2005). COX-2 inhibitors - A lesson in unexpected problems. New England Journal of Medicine, 352, 1131-1132.
24. Eisenberg, D. M., Kessler, R. C., Foster, C., Norlock, F. E., Calkis, D. R., & Delbanco, T. L. (1993). Unconventional medicine in the United States: Prevalence, costs, and patterns of use. New England Journal of Medicine, 328, 246-252.
25. Engelhart, M. J., Geerlings, M. I., Ruitenberg, A., van Swieten, J. C., Hofman, A., Witteman, J. C. M., et al. (2002). Dietary intake of antioxidants and risk of Alzheimer's disease. Journal of the American Medical Association, 287, 3223-3229.
26. Ernst, E., & Pittler, M. H. (1999). Gingko biloba for dementia: a systematic review of double-blind placebo-controlled trials. Clinical Drug Investigation, 17, 301-308.
27. Etminan, M., Gill, S., & Samii, A. (2003). Effect of non- steroidal anti-inflammatory drugs on risk of Alzheimer's disease: Systematic review and meta-analysis of observational studies. British Medical Journal, 327, 128-132.
28. Farah, M. J., Illes, J., Cook-Deegan, R., Gardner, H., Kandel, E., King, P., et al. (2004). Neurocognitive enhancement: What can we do and what should we do? Nature Reviews Neuroscience, 5, 421-425.
29. Gauthier, S. (2002). Advances in the pharmacotherapy of Alzheimer's disease. Canadian Medical Association Journal, 166, 616-623.
30. Gold, P. E. (2003). Acetylcholine modulation of neural systems involved in learning and memory. Neurobiology of Learning and Memory, 80, 194-210.
31. Gonzales, E. A., Mustelier, M. M., & Rey, J. A. (2005). Geriatric psychopharmacology. In S. S. Bush & T. A. Martin (Eds.), Geriatric neuropsychology: Practice essentials (pp. 401-428). New York: Psychology Press.
32. Granger, R., Staubli, U., Davis, M., Perez, Y., Nilsson, L., Rogers, G. A., et al. (1993). A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse, 15, 326-329.
33. Hall, S. (2003). The quest for a smart pill. Scientific American, 289, 54-65.
34. Halpern, S. (2005). You must remember this: Are there memory- enhancement products that work? Retrieved December 5, 2005, from http://slate.msn.com/id/ 2111758/
35. Hauser, S. L. (2004). The shape of things to come. Neurology, 63, 948-950.
36. Healy, M. (2004). Sharper minds. Retrieved December 20, 2004, from http://www.latimes.com/features/health/la-hesmartdrugs 20dec20.story
37. Heiskanen, O. (1995). Surgical management of unruptured cerebral aneurysms. In H. H. Schmidek & W. H. Sweet (Eds.), Operative neurosurgical techniques: Indications, methods, and results (3rd ed., pp. 1155-1162). Philadelphia: Saunders.
38. Hruby, P. (2005). Brainpower drugs coming for sports. Retrieved May 1, 2005, from http://washingtontimes.com/national/20050424-123622-9449r.htm
39. Ingvar, M., Ambros-Ingerson, J., Davis, M., Granger, R., Kessler, M., Rogers, G. A., et al. (1997). Enhancement by an ampakine of memory encoding in humans. Experimental Neurology, 146, 553-559.
40. in t' Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., et al. Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. New England Journal of Medicine, 345, 1515-1521.
41. Kaufman, S. R., Shim, J. K., & Russ, A. J. (2004). Revisiting the biomedicalization of aging: Clinical trends and ethical challenges. The Gerontologist, 44, 731-738.
42. Kaye, J. A., Swihart, T., Howieson, D., Dame, A., Moore, M. M., Karnos, T., et al. (1997). Volume loss the hippocampus and temporal lobe in healthy elderly persons destined to develop dementia. Neurology, 48, 1297-1304.
43. Knapp, S., & Vandecreek, L. (2004). A principle-based analysis of the 2002 American Psychological Association ethics code. Psychotherapy: Theory, Research, Practice, Training, 41, 247-254.
44. Kramer, A. F., Bherer, L., Colcombe, S. J., Dong, W., & Greenough, W. T. (2004). Environmental influences on cognitive and brain plasticity during aging. Journal of Gerontology: Medical Sciences, 59A, 940-957.
45. Lagarde, D., Batejat, D., Van Beers, P., Sarafian, D., & Pradella, S. (1995). Interest of modafinil, a new psychostimulant, during a sixty-hour sleep deprivation experiment. Fundamental and Clinical Pharmacology, 9, 1-9.
46. Laurin, G., Masaki, K. H., Foley, D. J., White, L. R., & Launer, L. J. (2004). Midlife dietary intake of antioxidants and risk of late-life incident dementia. The Honolulu-Asia Aging Study. American Journal of Epidemiology, 159, 959-967.
47. Lees-Haley, P. R., & Fox, D. D. (2004). Forensic neuropsychology: Still controversial after all these years. Brain Injury Professional, 1(2), 6-10.
48. Lezak, M. D., Howieson, D. B., & Loring, D. W. (2004). Neuropsychological assessment (4th ed.). New York: Oxford University Press.
49. Lynch, G. (2003). Memory enhancement: The search for mechanism-based drugs. Nature Neuroscience Supplement, 5, 1035-1038.
50. Mariani, S. M. (2003). Neuroethics: How to leave the cave without going astray. Medscape General Medicine, 5(4). Retrieved December 17, 2003, from http://www.medscape.com/viewarticle/465150
51. McAllister, T. W., Flashman, L. A., Sparling, M. B., & Saykin, A. J. (2004). Working memory deficits after traumatic brain injury: Catecholinaminergic mechanisms and prospects for treatment. Brain Injury, 18, 331-350.
52. Morris, M. C., Evans, D. A., Bienias, J. L., Tangney, C. C., Bennett, D. A., Aggarwal, N., et al. (2002). Dietary intake of antioxidant nutrients and the risk of incident Alzheimer's disease in a biracial community study. Journal of the American Medical Association, 287, 3230-3237.
53. Moser, D. J., Jorge, R. E., Manes, F., Paradiso, S., Benjamin, M. L., & Robinson, R. G. (2002). Improved executive functioning following repetitive transcranial magnetic stimulation. Neurology, 58, 1288-1290.
54. Nakagawa, T., & Hashi, K. (1994). The incidence and treatment of asymptomatic, unruptured cerebral aneurysms. Journal of Neurosurgery, 80, 217-223.
55. Nordberg, A. (2003). Toward an early diagnosis and treatment of Alzheimer's disease. International Psychogeriatrics, 15, 223-237.
56. Oken, B. S., Storzbach, D. M., & Kaye, J. A. (1998). The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Archives of Neurology, 55, 1409Y1415.
57. Phillips, M. (2004). An asterisk for Bonds? Retrieved December 27, 2004, from http://www.montereyherald.com/mld/monterey herald/sports/10459134.htm
58. President's Council on Bioethics. (2003). Beyond therapy: Biotechnology and the pursuit of happiness. Retrieved December 1, 2004, from http://www.bioethics.gov/reports/beyondtherapy
59. Rockwood, K., Kirkland, S., Hogan, D. B., MacKnight, C., Merry, H., Verreault, R., et al. (2002). Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Archives of Neurology, 59, 223-227.
60. Rusinek, H., De Santi, S., Frid, D., Tsui, W.-H., Tarshish, C. Y., Convit, A., et al. (2003). Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. Radiology, 229, 691-696.
61. Soreq, H., & Seidman, S. (2001). Acetylcholinesterase: New roles for an old actor. Nature Reviews Neuroscience, 2, 294-302.
62. Staubli, U., Rogers, G., & Lynch, G. (1994). Facilitation of glutamate receptors enhances memory. Proceedings of the National Academy of Sciences U S A, 91, 777-781.
63. Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997). Risk of Alzheimer's disease and duration of NSAID use. Neurology, 48, 626-632.
64. Svensson, A.-L., & Giacobini, E. (2000). Cholinesterase inhibitors do more than inhibit cholinesterase. In: E. Giacobini (Ed.), Cholinesterases and cholinesterase inhibitors (pp. 227-235). London: Martin Dunitz.
65. Topol, E. J. (2005). Arthritis medicines and cardiovascular events-"House of Coxibs". Journal of the American Medical Association, 293, 336-338.
66. Vila, J. F., Balcarce, P. E., Abiusi, G. R., Dominguez, R. O., Subbotina, N., & Pisarello, J. B. (1999). Oxigenoterapia hiperbárica en el síndrome frontal subcortical por enfermedad de [Hyperbaric oxygenation in subcortical frontal syndrome due to small artery disorders with leukoaraiosis.] Revista de Neurologia, 28, 655-660.
67. Wallace, D. J., Silverman, S., Goldstein, J., & Hughes, D. (1995). Use of hyperbaric oxygen in rheumatic diseases: Case report and critical analysis. Lupus, 4, 172-175.
68. Wolpe, P. R. (2002). Treatment, enhancement, and the ethics of neurotherapeutics. Brain and Cognition, 50, 387-395.
69. Yesavage, J. A., Mumenthaler, M. S., Taylor, J. L., Friedman, L., O'Hara, R., Sheikh, J., et al. (2002). Donepezil and flight simulator performance: Effects on retention of complex skills. Neurology, 59, 123-125.
70. Zamrini, E., McGwin, G., & Roseman, J. M. (2004). Association between statin use and Alzheimer's disease. Neuroepidemiology, 23(1-2), 94-98.